AfterRaise/Companies/FORE Biotherapeutics

FORE Biotherapeutics

USAPhiladelphiaBiotech & PharmaSeries D

Overview

Where FORE Biotherapeutics is now

FORE Biotherapeutics announced a Series D round of $67M on 8 July 2026, led by SR One.

Observed Described in the funding announcement as "registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer". Source

Latest round
Series D
Amount
$67M
Announced
8 July 2026
Headquarters
Philadelphia, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
SR One
Also participating
TaiAx, LG Technology Ventures, Primer Ventures and Axil, and all existing investors, including OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Capital, Novartis Venture Fund, Windham Life Science Partners, Samsung and 3B Capital
Relevant leadership
CEO William Hinshaw

Current direction Inferred

What this company is working on

Regulatory

Read from the company's own description of what the funding supports.

Momentum Inferred

AfterRaise Score

73
Building momentum
1 funding signal in the last 90 days
Funding recency
34/40
announced within the last 60 days
Round scale
19/25
round size relative to the market
Funding stage
20/20
Series D
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Growth timeline

What has happened so far

  • 8 July 2026
    $67M Series D
    Led by SR One.

Observed The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

Moves

Published by the company

Share a Move

No company-published Moves yet

AfterRaise has the funding facts for FORE Biotherapeutics from public sources. What it does not have is what the company is doing next, in the company's own words. That part only they can write.

Work here? Publish the first Move

Opportunities

Work this company has opened

No open Opportunities listed

Jobs, projects, partnerships and advisory needs appear here once the company has claimed its room and published them.

Work here? Open the first one

Open to

Who may approach FORE Biotherapeutics

Not yet specified

FORE Biotherapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Work here?

This room belongs to FORE Biotherapeutics.

Claim it to publish Moves in your own words, open Opportunities, choose who may approach you, and see the offers of help you have received. Everything you publish is reviewed before it appears.

Also moving

Other Biotech & Pharma companies

See the sector